Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-05-31Clinical Trial Update: Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas [Phase 1, Phase 2]
Phase 1/2 trial investigating oral decitabine with tetrahydrouridine as epigenetic priming to enhance pembrolizumab in inoperable/unresectab…
-
CLINICAL_TRIALS trial_result · 2023-05-31Clinical Trial Update: Exemestane in Post-Menopausal Women With NSCLC [Phase 2]
Phase 2 trial evaluating exemestane in post-menopausal women with non-small cell lung cancer has completed with results posted.
-
FDA approval · 2023-05-31FDA Approved: GEFITINIB — Original Application (Natco Pharma USA LLC)
The FDA approved Natco Pharma USA LLC's original ANDA for Gefitinib, enabling a generic version of the cancer drug to enter the market.
-
CLINICAL_TRIALS trial_result · 2023-05-25Clinical Trial Update: The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib
A completed trial evaluating how long NSCLC patients with EGFR mutations benefit from sequential EGFR-TKI therapy (afatinib followed by osim…
-
CLINICAL_TRIALS trial_result · 2023-05-25Clinical Trial Update: Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC [Phase 2]
Phase 2 trial evaluating tislelizumab in combination with pemetrexed and carboplatin for brain metastases in non-squamous non-small cell lun…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-05-25Clinical Trial Update: Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer [Phase 1, Phase 2]
Phase 1/2 trial evaluating cetuximab with gemcitabine and carboplatin in stage IV non-small cell lung cancer has completed.
-
FDA approval · 2023-05-22FDA Approved: PEMRYDI RTU — Original Application (Amneal Pharmaceuticals LLC)
FDA approved PEMRYDI RTU (pemetrexed disodium) from Amneal Pharmaceuticals as an Original Application, providing a ready-to-use formulation …
-
CLINICAL_TRIALS trial_result · 2023-05-19Clinical Trial Update: Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors [Phase 1]
Phase 1 study evaluating the safety of the CHK1 inhibitor VX-970 (M6620) in combination with whole-brain radiation therapy for brain metasta…
-
CLINICAL_TRIALS trial_result · 2023-05-19Clinical Trial Update: A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC [Phase 2]
Phase 2 trial evaluating SHR-1701 with or without chemotherapy in stage III non-small cell lung cancer is ongoing with unknown status.
-
CLINICAL_TRIALS trial_result · 2023-05-17Clinical Trial Update: A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy [Phase 3]
Phase 3 trial comparing atezolizumab to single-agent chemotherapy in treatment-naïve NSCLC patients unsuitable for platinum therapy complete…
-
CLINICAL_TRIALS trial_result · 2023-05-16Clinical Trial Update: To Evaluate the Efficacy and Safety of TQB3728 Tablets in Sequential Maintenance of TQB2450 Injection Therapy in Patients After Sequential or Concurrent Chemoradiation for Locally Advanced Non-small Cell Lung Cancer. [Phase 1, Phase 2]
A Phase 1/2 trial evaluating the efficacy and safety of TQB3728 tablets following TQB2450 injection therapy as maintenance in locally advanc…
-
CLINICAL_TRIALS trial_result · 2023-05-12Clinical Trial Update: Immunotherapy by Nivolumab for HIV+ Patients [Phase 2]
Phase 2 trial update evaluating immunotherapy with nivolumab in HIV-positive patients with metastatic or stage IIIB non-small cell lung canc…
-
CLINICAL_TRIALS trial_result · 2023-05-10Clinical Trial Update: Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200). [Phase 3]
Phase 3 trial comparing sotorasib (AMG 510) against docetaxel in KRAS G12C-mutated advanced/metastatic non-small cell lung cancer; results w…
-
CLINICAL_TRIALS trial_result · 2023-05-10Clinical Trial Update: Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200). [Phase 3]
Phase 3 trial comparing AMG 510 (sotorasib) with docetaxel in KRAS G12C-mutated advanced/metastatic non-small cell lung cancer has completed…
-
CLINICAL_TRIALS trial_result · 2023-05-10Clinical Trial Update: Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC. [Phase 2]
Phase II trial update exploring induction chemotherapy with chemoradiotherapy +/- durvalumab followed by consolidation immunotherapy in rese…
-
CLINICAL_TRIALS trial_result · 2023-05-09Clinical Trial Update: A Phase III Trial of Neoadjuvant Sintilimab and Chemotherapy for NSCLC Harboring No Driver Mutations [Phase 3]
A Phase III trial evaluating neoadjuvant Sintilimab plus chemotherapy for non-small cell lung cancer without driver mutations is in progress…
-
CLINICAL_TRIALS trial_result · 2023-05-08Clinical Trial Update: Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies [Phase 1, Phase 2]
Pfizer's PD-1 inhibitor sasanlimab (PF-06801591) is being studied in Phase 1/2 in adults with advanced cancers, including non-small-cell lun…
-
CLINICAL_TRIALS trial_result · 2023-05-08Clinical Trial Update: Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations [Phase 2]
Phase 2 trial update investigating disitamab vedotin in combination therapy for locally advanced or metastatic non-small cell lung cancer wi…
-
CLINICAL_TRIALS trial_result · 2023-05-03Clinical Trial Update: Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors) [Phase 2]
Phase 2 trial evaluating toripalimab in combination with chemotherapy and antiangiogenic agents for non-small cell lung cancer after failure…
-
CLINICAL_TRIALS trial_result · 2023-05-01Clinical Trial Update: G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer [Phase 1, Phase 2]
Phase 1/2 trial evaluating G1T38 in combination with osimertinib for EGFR-mutant non-small cell lung cancer has completed with results poste…
-
CLINICAL_TRIALS trial_result · 2023-05-01Clinical Trial Update: Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Positive Non-Small-Cell Lung Cancer [Phase 2, Phase 3]
Phase 2/3 trial evaluating hippocampal-sparing prophylactic cranial irradiation in patients with pathologically nodal positive non-small-cel…
-
FDA approval · 2023-04-26FDA Approved: GEFITINIB — Original Application (Teva Pharmaceuticals, Inc.)
FDA approved Teva Pharmaceuticals' generic Gefitinib under an Original Application (ANDA 208913). The approval enables Teva to market Gefiti…
-
CLINICAL_TRIALS trial_result · 2023-04-25Clinical Trial Update: Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial) [Phase 2]
Phase 2 Lung-MAP non-match trial evaluating ramucirumab plus pembrolizumab versus standard of care in stage IV or recurrent non-small cell l…
-
CLINICAL_TRIALS trial_result · 2023-04-25Clinical Trial Update: KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent [Phase 2, Phase 3]
A clinical trial evaluating KN046 plus lenvatinib in advanced non-small cell lung cancer after failure of anti-PD-(L)1 therapy has been term…
-
FDA approval · 2023-04-24FDA Approved: LUMAKRAS — Supplemental Application (Amgen Inc)
The FDA approved a supplemental application for LUMAKRAS (sotorasib) filed by Amgen Inc. This action updates the drug labeling to include th…